Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients’ Voice or a Missed Opportunity-Reference-Cited by-同舟云学术

Evaluation of Patient-Reported Outcomes (PROs) Protocol Content and Reporting for Clinical Trials that Lead to the approval of frontline Immune Checkpoint Blockade Combination for Patients with Advanced Renal Cell Carcinoma - The Patients’ Voice or a Missed Opportunity

Published:2021-12 Issue: Volume: Page:
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Chadha Juskaran^ORCID,Adashek Jacob J.^ORCID,Jim Heather,Kim Youngchul,Semaan Adele,Chakiryan Nicholas H,Safa Houssein^ORCID,Hajiran Ali,Sexton Wade^ORCID,Gilbert Scott M,Manley Brandon J,Spiess Philippe E,Chahoud Jad

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference36 articles.

1. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int. Immunopharmacol.,2018

2. Delivery technologies for cancer immunotherapy;Riley;Nat Rev Drug Discovery,2019

3. Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) - Full Text View - ClinicalTrials.gov. Accessed May 6, 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT02231749

4. Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) - Study Results - ClinicalTrials.gov. Accessed May 6, 2021. Available at: https://clinicaltrials.gov/ct2/show/results/NCT02853331

5. A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma - Full Text View - ClinicalTrials.gov. Accessed May 6, 2021. Available at: https://clinicaltrials.gov/ct2/show/NCT03141177

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors;JCO Clinical Cancer Informatics;2024-07

2. Re: Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, et al. A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. Eur Urol Oncol. 2023;6:339–348;European Urology Oncology;2024-02

3. 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis;eClinicalMedicine;2024-02

4. Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment;Nature Reviews Urology;2023-03-16

5. 15 Years of Patient-Reported Outcomes in Clinical Trials Leading to Gu Cancer Drug Approvals: A Focus on the Quality of Data Reporting and Analysis;2023